PROTAGONIST THERAPEUTICS
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7707 Gateway Blvd Ste 140, Newark, Calif...Phone Number
(510) 474-0170Website
www.protagonist-inc.comRevenue
$74.1 MillionStock Symbol
PTGXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About PROTAGONIST THERAPEUTICS
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The company was founded in 2006 and is headquartered in Newark, California.Explore more
PROTAGONIST THERAPEUTICS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PROTAGONIST THERAPEUTICS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
PROTAGONIST THERAPEUTICS, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at PROTAGONIST THERAPEUTICS
Funding: Get notified immidiatlly once PROTAGONIST THERAPEUTICS has new funding data
Earning: See what the market has to say on PROTAGONIST THERAPEUTICS recently announced quarterly report
Product Launch: Get notified when PROTAGONIST THERAPEUTICS launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if PROTAGONIST THERAPEUTICS has recently received funding, and reach out quickly before it becomes old news!
Click to see if PROTAGONIST THERAPEUTICS had a recent Job posting/layoffs
Check out if PROTAGONIST THERAPEUTICS is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to PROTAGONIST THERAPEUTICS
Compare insights from companies similar to PROTAGONIST THERAPEUTICS, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PROTAGONIST THERAPEUTICS
$74.1M
51-200
Public
$115M
2006
AB
Abha BommireddiExecutive Vice President & Chief of Staff
$192.8M
201-500
Private
$488.9M
2006
JD
Jayne DonnellyVice President, Executive Operations and Administration
Company Profile Activity
Activity Insights
PROTAGONIST THERAPEUTICS is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PROTAGONIST THERAPEUTICS is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PROTAGONIST THERAPEUTICS.
PROTAGONIST THERAPEUTICS financials insights
Gather financial insights about PROTAGONIST THERAPEUTICS, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$115M
PROTAGONIST THERAPEUTICS Tech Stack
A closer look at the technologies used by PROTAGONIST THERAPEUTICS
See more technologies
Most Recent Scoops
Project
PROTAGONIST THERAPEUTICS has announced that its previously 50/50 co-development and co-commercialization partnership with Takeda for Rusfertide has been restructured, with PROTAGONIST THERAPEUTICS opting out and Takeda assuming an outright license for the drug, which has a PDUFA date anticipated in Q3.
Project
PROTAGONIST THERAPEUTICS has announced that its oral IL-17 program is currently in a Phase I study enrolling more than 100 healthy volunteers, with results expected in Q3, targeting once-daily oral delivery benchmarked against EC50 and EC90 trough levels at 24 hours.
Medical Research, Pharmaceuticals, Clinical Operations
Project
PROTAGONIST THERAPEUTICS has announced that its oral Triple-G obesity candidate has been engineered to combine tirzepatide's GLP-GIP dual potency with added GCG activity, differentiating it from retatrutide, with the goal of maximizing weight loss while reducing muscle mass loss and minimizing nausea and vomiting side effects.
Bioengineering, Pharmaceuticals
Person-Based
Product Launch
Person-Based
Healthcare Operations
PROTAGONIST THERAPEUTICS News & Media
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ranks 4th on this list. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been a consistent feature in the 13F portfolio of Farallon Capital since the fourth quarter of 2017. Back then, this position comprised 900,000 shares. In the quarters since […]Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ranks 10th on this list. Elite investors have been positioning themselves in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stock as the firm transforms from a clinical-stage biotech to a high-margin commercial royalty engine. An important reason for interest […]Protagonist Therapeutics (PTGX) CMO exercises options, sells 15000 shares - Stock Titan
Protagonist Therapeutics CMO Arturo Molina exercised 15,000 options at $8.04 and sold 15,000 shares at a $104.79 average, leaving 84,115 PTGX shares held.Do Protagonist Therapeutics’ (PTGX) Derisked Drugs Have Blockbuster Potential?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the Russell 2000 Growth Index in the fourth quarter, after a strong first three quarters of 2025. Market’s overreactions to earnings disappointments in the technology sector and […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding PROTAGONIST THERAPEUTICS
Sign Up For FreeTo access detailed company insights
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The company was founded in 2006 and is headquartered in Newark, California... Read More
